GO
Loading...

Novartis AG

More

  • CHICAGO, May 31- Cancer doctors should consider the financial as well as the medical impact of treatment for patients as healthcare costs continue to grow faster than the overall economy, according to experts in Chicago at the annual meeting of the world's largest organization of oncologists.

  • NEW YORK, May 29- A federal judge on Thursday refused to dismiss a U.S. government lawsuit accusing Novartis AG of civil fraud for having conducted two illegal kickback schemes to boost sales of drugs covered by Medicare and Medicaid.

  • NEW YORK, May 29- A federal judge has refused to dismiss a U.S. government lawsuit accusing Novartis AG of civil fraud for having conducted two illegal kickback schemes to boost sales of drugs covered by Medicare and Medicaid.

  • LONDON, May 29- GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter. Private equity firms approached by GSK include Advent International, Blackstone and KKR, the sources said, and the drugmaker is being advised by Lazard.

  • GSK invites private equity bid for drugs: Sources Thursday, 29 May 2014 | 12:34 PM ET
    A GlaxoSmithKline Plc logo sits on a sign outside the company's headquarters in London, U.K.

    GSK has invited private equity firms to consider making offers for a range of its older drugs, three people with direct knowledge of the matter said.

  • Immuno-what? How these cancer therapies work Thursday, 29 May 2014 | 12:27 PM ET
    Laboratory which develops therapeutic vaccinations to treat cancer.

    A key theme at this year's ASCO meeting will be immunotherapies. How do these treatments work?

  • LONDON, May 29- GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter. Private equity firms approached by GSK include Advent International, Blackstone and KKR, the sources said, and the drugmaker is being advised by Lazard.

  • GSK invites private equity bids for older drugs -sources Thursday, 29 May 2014 | 11:09 AM ET

    LONDON, May 29- GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs, according to two people with direct knowledge of the matter. The move is part of a reshaping of the drugmaker's business, which also involves a major asset swap deal with Novartis.

  • Why Pfizer should try to buy Bristol-Myers Tuesday, 27 May 2014 | 1:21 PM ET
    Viagra made by Pfizer and Nexiam made by AstraZeneca.

    What's next for Pfizer, now that its bid for AstraZeneca has been laid to rest, at least temporarily. Analysts weigh in with their views.

  • Chinese city targets pharma firms in graft crackdown Tuesday, 27 May 2014 | 9:08 AM ET

    SHANGHAI, May 27- China's eastern city of Hangzhou is cracking down on graft in the healthcare sector, according to an internal memo from the local government, putting more pressure on global drugmakers operating in the country.

  • LONDON/ NEW YORK, May 26- Pfizer abandoned its attempt to buy AstraZeneca for nearly 70 billion pounds on Monday as a deadline approached without a last-minute change of heart by the British drugmaker.

  • LONDON/ NEW YORK, May 26- Pfizer said on Monday it had abandoned its current attempt to buy AstraZeneca for nearly 70 billion pounds as a deadline approached without a last-minute change of heart by the British drugmaker. Its decision to quit the stage, at least for now, had been widely expected after AstraZeneca refused its final offer of 55 pounds a share.

  • A bitter pill as China crackdowns squeeze pharma margins Saturday, 24 May 2014 | 10:00 PM ET

    China has been a magnet for the big global pharmaceutical companies and other healthcare firms as growth slows in Europe and the United States. While global drugmakers withhold their China profit figures, the analysis suggests profit growth is harder to come by- a concern as many global firms look to China as a future growth driver.

  • Why there's no end in sight for higher drug costs Thursday, 22 May 2014 | 7:06 AM ET
    About 40 protesters from across the country converged on Gilead Sciences headquarters in Foster City, Calif., Nov. 14, 2012, calling on the drug maker to lower prices for its Stribild AIDS medication.

    The mounting scrutiny of prescription drug prices in the U.S. reached fever pitch with total spending last year rising 3.2 percent, to $329.2 billion.

  • *China anti-trust watchdog visits Roche office. *China cracking down on wider pharma sector. SHANGHAI/ ZURICH, May 22- Swiss drugmaker Roche Holding AG said it had been visited by a unit of China's anti-trust regulator- a move that comes amid a widening crackdown on corruption and high prices in the country's pharmaceutical sector.

  • FRANKFURT, May 21- Hedge fund Magnetar Capital is suing U.S. drugs wholesaler McKesson, saying its acquisition of German peer Celesio short-changed minority shareholders and bondholders by around 370 million euros.

  • Is bubble trouble looming for the 'crazy' M&A market? Wednesday, 21 May 2014 | 4:58 AM ET

    Global M&A activity has reached levels not seen since 2008, fueling concern about bubbles forming in the market.

  • May 19- Ophthotech Corp said it could potentially receive over $1 billion in payments as part of a licensing deal for its experimental eye drug with Novartis AG. Ophthotech's shares rose as much as 29 percent in trading after the bell.

  • May 19- Ophthotech Corp said it granted the rights to market its experimental eye drug outside the United States to a unit of Novartis AG. Ophthotech's shares rose as much as 29 percent in trading after the bell. Ophthotech said Novartis would develop and market the technology such as a pre-filled syringe to deliver the injectable eye drug.

  • May 19- Ophthotech Corp said it granted the rights to market its experimental eye drug outside the United States to a unit of Novartis AG. Ophthotech said it could receive immediate payments including upfront fees of $200 million and milestone payments of $130 million.